Nozinan (Levomepromazine Maleate)

Levomepromazine, the active ingredient in Nozinan, is a phenphen presented as a strength/form for oral use. It is employed in the management of severe agitation, nausea, and psychotic disorders, particularly in palliative care settings. GNH USA supplies Nozinan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

GNH USA supplies Nozinan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Levomepromazine is a low‑potency phenothiazine antipsychotic that acts on multiple neurotransmitter pathways, especially dopamine and serotonin receptors.

- Severe agitation in palliative care: helps control distressing restlessness and anxiety. - Nausea and vomiting: provides relief when other anti‑emetics are insufficient. - Psychotic disorders: reduces hallucinations and delusions in schizophrenia and related conditions.

Levomepromazine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Drowsiness: patients often feel sleepy. - Dry mouth: reduced salivation is frequent. - Constipation: slowed gastrointestinal motility. - Orthostatic hypotension: drop in blood pressure on standing. - Blurred vision: visual accommodation may be affected. - Weight gain: increased appetite can lead to weight increase.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: a life‑threatening reaction with fever and muscle rigidity. - Tardive dyskinesia: persistent involuntary movements. - Severe hypotension: marked drop in blood pressure. - Cardiac arrhythmias: irregular heart rhythms. - Agranulocytosis: dangerously low white‑blood‑cell count. - Hepatic dysfunction: liver enzyme elevations.

When prescribing Levov…

- Monitor    :    ... -  …  ...  ...  ....  … … ... … … ... … …